Hua Yuan Zheng Quan·2025-10-15 08:56Investment Rating - The industry investment rating is "Positive" (maintained) [4][6] Core Viewpoints - The report highlights the release of the "Guiding Opinions on Promoting the High-Quality Development of Health Insurance" by the National Financial Regulatory Administration, which includes six key points aimed at developing commercial medical insurance, nursing insurance, disability insurance, and disease insurance, promoting the integration of health insurance and health management, and facilitating the coordinated development of the health industry [4][5] - The support for insurance companies with good regulatory ratings to develop participating long-term health insurance is expected to significantly impact listed insurance companies [5][6] - The report anticipates that the actual payment costs for participating disease insurance may decrease, opening up innovation opportunities for insurance products [6] Summary by Sections Industry Performance - The growth rate of health insurance premiums has declined from a peak of 40%-70% between 2014-2016 to below 10% since 2021, indicating a challenging sales environment for new long-term disease insurance policies [5] - The proportion of high-value critical illness insurance has decreased from 64% in 2020 to 56.4% in 2023 [5][11] Sales Trends - The sales of long-term disease insurance have weakened due to previous extensive coverage and a reduction in the preset interest rate from 3.5% to 2%, leading to higher policy prices [5][6] - Future sales growth may come from new births or previously uncovered populations, as well as existing policyholders increasing their coverage after price adjustments [5][6] Product Innovation - The report expects further guidelines on the development of participating disease insurance products, allowing insurance companies to innovate and meet specific customer needs [6] - The current environment for insurance industry spreads is improving, supporting the overall positive outlook for the industry [6][7]